Independence Blue CrossMedicare Advantage · Administrative · Medical Policy · NJ · Transplant Surgery, Infectious Disease, Internal Medicine +1 moreLow impact
MA06.018a, Immune Cell Function Assay
Effective date
Not stated in the notice
Identified
Jun 25, 2026
Summary
This is a reissue with no substantive changes to Independence Blue Cross Medicare Advantage policy MA06.018a. The policy continues to classify immune cell function assay (ImmuKnow) as experimental/investigational and non-covered for all indications, including transplant monitoring. Despite FDA clearance, the company maintains its position that safety and effectiveness cannot be established through peer-reviewed literature review.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
02This is a routine annual reissue with no changes to coverage policy.
03Continue current billing practices: deny all claims for CPT 86352 (immune cell function assay) submitted under Independence Blue Cross Medicare Advantage plans.
04Maintain existing edits in billing system that flag this code as non-covered/experimental.
Codes mentioned
86352
Original notice
MA06.018a, Immune Cell Function Assay
medpolicy.ibx.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.